China Resources Double Crane: Subsidiary products pass generic drug consistency evaluation.

China Resources Shuanghe announced that its wholly-owned subsidiary Anhui Shuanghe Pharmaceutical Co., Ltd. and its holding subsidiary Shuanghe Tian'an Pharmaceutical Co., Ltd. have respectively received the "Drug Supplementary Application Approval Notice" for glycerin fructose sodium chloride injection and metformin empagliflozin tablets issued by the National Medical Products Administration. Glycerin fructose sodium chloride injection has passed the generic drug quality and efficacy consistency evaluation, mainly used for cerebrovascular diseases, etc. As of the announcement date, the company's cumulative research and development investment for this drug is 2.7253 million yuan, and the total sales in the domestic market in 2024 are estimated to be 658 million yuan. The metformin empagliflozin tablets have been approved for a change in the marketing authorization holder, with the drug approval number remaining unchanged. As of the announcement date, the company's cumulative research and development investment for this drug is 5.1956 million yuan, and the total sales in the domestic market in 2024 are estimated to be around 340 million yuan.